# Multiple Myeloma — Fifth Annual National General Medical Oncology Summit

Page: https://stenobird.com/podcast/hematologic-oncology-update-916423/multiple-myeloma-fifth-annual-national-general-medical-oncology-summit
Text version: https://stenobird.com/podcast/hematologic-oncology-update-916423/multiple-myeloma-fifth-annual-national-general-medical-oncology-summit.md
Podcast: [Hematologic Oncology Update](https://stenobird.com/podcast/hematologic-oncology-update-916423)
Published: 2026-06-18T21:00:00+00:00
Episode link: https://hematologic-oncology.captivate.fm/episode/6009-gmo26-mm
Audio file: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/e47c4f1a-c22f-4664-80b0-b550087ec77d.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/multiple-myeloma-fifth-annual-national-general-medical-oncology-summit
Duration seconds: 2825

## Resource

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics: Introduction (0:00) Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30) Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33) CME information and select publications

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/multiple-myeloma-fifth-annual-national-general-medical-oncology-summit/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hematologic-oncology-update-916423/multiple-myeloma-fifth-annual-national-general-medical-oncology-summit.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.